- Conditions
- Bedwetting, Nocturnal Enuresis, Urinary Incontinence
- Interventions
- gogoband, SNEA group
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,348
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Medical Chart Review
- Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Not listed
- Enrollment
- 2,240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 629
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 405 more
- Conditions
- Bronchiolitis Acute Viral
- Interventions
- Educational Outreach, Audit & Feedback (unit level), Audit & Feedback (real time, individual-level), Clinical Pathway Integrated into Electronic Health Record
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Months and older
- Enrollment
- 9,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Davis, California • Encinitas, California + 42 more
- Conditions
- Healthy, Sickle Cell Anemia
- Interventions
- Placebo, PF-07209326
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
- Conditions
- Acute Ischemic Stroke, Blood Pressure Variability
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Healthy Subjects
- Interventions
- Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 586
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
- Conditions
- Atrial Fibrillation
- Interventions
- Multi-Electrode RF Balloon Catheter
- Device
- Lead sponsor
- Biosense Webster, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 32 more
- Conditions
- Recurrent Endometrial Cancer
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Left Ventricular Hypertrophy
- Interventions
- Customized discharge and expedited referral instructions
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 1999
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 24 more
- Conditions
- Drug Dependence
- Interventions
- Primary Care Counseling, Cognitive-behavioral psychotherapy
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab, Daratumumab, Lenalidomide, Dexamethasone, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 67
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Clovis, California + 53 more
- Conditions
- Aortic Stenosis
- Interventions
- CoreValve Evolut R TAVR system
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- Not listed
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 18 more
- Conditions
- Sleep Deprivation
- Interventions
- white noise, usual care
- Device · Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Tuberculosis, Hiv
- Interventions
- Rifapentine daily, Rifapentine weekly
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depressive Disorder
- Interventions
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 35
- States / cities
- Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
- Conditions
- McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
- Interventions
- Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
- Procedure · Diagnostic Test
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Clinically Significant Portal Hypertension
- Interventions
- Placebo, Sorafenib
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- Peripheral Artery Disease
- Interventions
- Tack Endovascular System
- Device
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 36
- States / cities
- Yuma, Arizona • Little Rock, Arkansas • Beverly Hills, California + 31 more
- Conditions
- Heart Failure
- Interventions
- HM II (HeartMate II LVAD), OMM (Optimal Medical Management)
- Device · Drug
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 52
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 223
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
- Conditions
- Cystic Fibrosis
- Interventions
- Tezacaftor/Ivacaftor, Ivacaftor, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more